HEMATOLOGY

In an interview with Targeted Oncology, George Nahas, DO, discussed relevant research on chimeric antigen receptor therapy, bispecifics, and more that are moving the needle in multiple myeloma research.

The partial clinical hold on the TakeAim Leukemia trial exploring emavusertib in patients with acute myeloid leukemia and myelodysplastic syndrome has been lifted.

During a Targeted Oncology™ Case-Based Roundtable™ event, Danko Martincic, MD, outlined the definition, risk factors, and treatment for patients with tumor lysis syndrome.

Yi-Bin Chen leads the panel in a review of various GVHD prophylaxis regimens.

In the first article of this series, Elias Jabbour, MD, gives an overview of myelodysplastic syndrome and discusses the evolving treatment landscape.

In the first installment of this series, Elias Jabbour, MD, provides an overview of myelodysplastic syndrome, discusses the current treatment landscape for lower-risk MDS, and offers insights on factors that influence treatment selection.

A phase 1 study is assessing the safety and tolerability of briquilimab in patients with lower-risk myelodysplastic syndrome.

Catherine Lee explains risk factors that may contribute to the likelihood of a patient developing graft versus host disease.

Updates to the NCCN guidelines will help clinicians treat their patients with acute lymphoblastic leukemia, B-cell lymphomas, pediatric acute lymphoblastic leukemia, and pediatric aggressive mature B-cell lymphomas on high-dose methotrexate.

Yazan Samhouri, MD, discusses the latest advancements in the diffuse large B-cell lymphoma treatment landscape.

Following positive data from the phase 3 IMerge study of imetelstat, the FDA has received a new drug submission for the agent for the treatment of patients with relapsed or refractory myelodysplastic syndrome.

Rami Komrokji, MD, discusses the different systems of classifying myelodysplastic syndrome.

OMS906, a MASP-3 inhibitor, demonstrated clinical efficacy in a proof-of-concept study for patients with paroxysmal nocturnal hemoglobinuria, according to an interim analysis presented at the 2023 EHA Congress.

In a phase 3 study, imetelstat has shown prolonged transfusion independence and hemoglobin increase in the relapsed or refractory myelodysplastic syndrome population.

Results from the phase 3 COMMANDS study were presented in a press briefing ahead of the 2023 ASCO Annual Meeting.

The FDA has approved avapritinib for adult patients with indolent systemic mastocytosis based on findings from the phase 2 PIONEER trial.

A phase 3 trial evaluating roxadustat for the treatment of anemia in patients receiving concurrent chemotherapy for non-myeloid malignancies met its primary end point.

The proportion of patients with myelodysplastic syndromes who achieved red blood cell transfusion independence in the first 28 weeks was 47.5% for patients given roxadustat vs 33.3% for patients given placebo for the treatment of anemia.

Yazan Samhouri, MD, discusses some of the current research that his team at AHN is working on.

In an interview with Targeted Oncology, Adam J. Olszewski, MD, discussed mosunetuzumab and the rationale and findings of this phase 1b/2 study assessing the agent in elderly patients with diffuse large B-cell lymphoma.

Findings from the COMMANDS study in which luspatercept showed statistically significant and clinically meaningful improvements for patients with low-risk myelodysplastic syndrome, the FDA has set a target action date of August 28, 2023.

Multiple cases of unacceptable toxicity requiring dose reductions have occurred in a phase 1 study of MT-0169 in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The FDA has placed a partial clinical hold on the study

Gayathri Ravi, MD, discusses the role minimal residual disease plays in decision making and treating patients with hematologic malignancies.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hetty E. Carraway, MD, MBA, discussed with participants diagnosing and treating patients with BPDCN, as well as the remaining challenges in this space.

The largest registrational study of immune checkpoint inhibitor therapy in relapsed/refractory extranodal natural killer/T-cell lymphoma showed potent and durable antitumor activity with sugemalimab.

Abdulraheem Yacoub, MD, offers closing thoughts on the future myelofibrosis treatment landscape, with a focus on treatments under investigation.

A detailed overview on monitoring patients with myelofibrosis, and signs that a treatment isn’t effective.

An expert on myelofibrosis discusses recently updated data on momelotinib, which was recently submitted for FDA approval.

Abdulraheem Yacoub, MD, details the systemic therapy options for myelofibrosis and his approach to treatment sequencing.

A myelofibrosis expert discusses the indications for treatment initiation and transplantation for patients with myelofibrosis.